Search | Clinical Trials Finder

Conditions: Abnormal Uterine Bleeding, Unspecified, Uterine Bleeding Heavy
Interventions: EE 30mcg/LNG 150mcg, Placebo; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 14 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Sacramento, California • St Louis, Missouri

Conditions: Menorrhagia, Heavy Menstrual Bleeding, Heavy Uterine Bleeding
Interventions: Minitouch System; Device
Lead sponsor: MicroCube, LLC; Industry
Eligibility: 30 Years to 50 Years · Female only
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Newburgh, Indiana • Mason, Ohio • Austin, Texas

Conditions: Anemia, Iron Deficiency, Uterine Bleeding
Interventions: Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric], Ferrous Sulfate 65 mg elemental iron (325 mg tablets); Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infertility, Menorrhagia
Interventions: Salpingography; Procedure
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Heavy Menstrual Bleeding, Menorrhagia, Hypermenorrhea
Interventions: Norethindrone acetate pretreatment, No pretreatment; Drug · Other
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Iron Deficiency Anemia Treatment, Iron Deficiency, Iron Deficiency (Without Anemia)
Interventions: FeoSol Original Iron Supplement Tablets, 21st Century Gelatin Capsules; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Menorrhagia
Interventions: Genesys HydroTherm Ablator, radiofrequency energy ablation device; Device
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Dysfunctional Uterine Bleeding
Interventions: Medroxyprogesterone 17-Acetate; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Menorrhagia
Interventions: tranexamic acid; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 12 Years to 16 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cypress, California

Conditions: Prostate Cancer
Interventions: low venous pressure general anesthesia, combined spinal-epidural anesthesia; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Uterine Fibroids (UF)
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Arlington, Virginia

Conditions: Uterine Fibroids, Heavy Menstrual Bleeding
Interventions: Estradiol/Norethindrone Acetate, Elagolix; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 51 Years · Female only
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 121
States / cities: Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 90 more

Conditions: Vaginal Bleeding
Interventions: Intrauterine system; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Morristown, New Jersey • Newark, New Jersey

Conditions: Menorrhagia
Interventions: Oral tranexamic acid, Oral Contraceptive Pills; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 21 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer, PSA, Infection
Interventions: Systematic Transrectal biopsy (TR-Bx), Targeted Transrectal biopsy (TR-Bx), Systematic Transperineal biopsy (TP-Bx), Targeted Transperineal biopsy (TP-Bx); Procedure
Lead sponsor: Albany Medical College; Other
Eligibility: Male only
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Albany, New York

Conditions: Menorrhagia, Blood Coagulation Disorders, Blood Platelet Disorders, Von Willebrand Disease, Hematologic Disease
Interventions: Tranexamic Acid, Desmopressin Acetate; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 6
States / cities: Atlanta, Georgia • East Lansing, Michigan • Rochester, Minnesota + 3 more

Conditions: Endometriosis
Interventions: Ulipristal; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Contraception
Interventions: Levonorgestrel IUS (Mirena, BAY86-5028); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 49
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 44 more

Conditions: Hematuria, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions: PuraStat; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: Male only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Adenomyosis
Interventions: Vaginal Bromocriptine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 55 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Heavy Menstrual Bleeding, Menorrhagia, Uterine Fibroids
Interventions: Levonorgestrel IUS, Tranexamic Acid; Drug
Lead sponsor: Shannon K. Laughlin-Tommaso; Other
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Uterine Hemorrhage
Interventions: Direct oral anticoagulant (DOACs), Warfarin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 961,985 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Menorrhagia
Interventions: Extended treatment regimen using Her Option Cryotherapy; Device
Lead sponsor: CooperSurgical Inc.; Industry
Eligibility: 30 Years to 100 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 7
States / cities: Phoenix, Arizona • Wellington, Florida • Burlington, Massachusetts + 4 more

Conditions: Vaginal Bleeding
Interventions: Tamoxifen Citrate 10Mg Tab, Estradiol, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 15 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Richmond, Virginia

Search by objective public record fields.

Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive

Minitouch Endometrial Ablation System Treatment for Menorrhagia: An Evaluation of Safety & Effectiveness

IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department

Hysteroscopic Assessment of Fallopian Tubal Patency

Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding

How Does Perimenopausal Menorrhagia Affect Women's Quality of Life and Cognitive Function?

Evaluation of the Endometrial Cavity After Endometrial Ablation

Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist

Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding

A Randomized Study of the Efficacy of Low Venous Pressure General Anesthesia Versus Combined Spinal-Epidural Anesthesia in Decreasing Blood Loss During Prostate Surgery

A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Does Skyla Insertion Timing Impact Bleeding?

Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study

Prostate Biopsy, Transrectal vs. Transperineal: Efficacy and Complications

Treatment and Management of Women With Bleeding Disorders

Ulipristal for Endometriosis-related Pelvic Pain

Mirena Extension Trial

RADA16 for Aquablation Day Case

Vaginal Bromocriptine for Treatment of Adenomyosis

Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System

Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot Trial